Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas

Myxoid liposarcoma(MLS) is a rare malignancy with an estimated incidence of 2 per million person years and belongs to the heterogeneous group of Soft Tissue Sarcomas(STS).[1] The standard treatment of primary MLS consists of surgery and RT.[2,3] The 5-year local control rates of 96-98% are to an important extent a result of the well-established exceptional clinical radiosensitivity of MLS.[4 –10] However, notwithstanding the excellent local control, disease specific mortality is predominantly determined by the 14-33% of patients who eventually develop distant metastases.[8–11] As major morbidity can be induced when distant metastases become symptomatic, effective strategies to achie ve local control of metastatic lesions are desired.

Source: Radiotherapy and Oncology - February 18, 2021 Category: Radiology Authors: Jules Lansu, Winan J. van Houdt, Kirsten van Langevelde, Piet L.A. van den Ende, Winette T.A. van der Graaf, Yvonne Schrage, Hester van Boven, Astrid N. Scholten, Rick L. Haas Tags: Original Article Source Type: research